Optimization of pyrazolopyridine 4-carboxamides with potent antimalarial activity for which resistance is associated with the P. falciparum transporter ABCI3

Affiliations

• 1 The Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, 3010, Australia.
• 2 Research School of Biology, Australian National University, Canberra, 2601, Australia.
• 3 TCG Lifesciences, Kolkata, West Bengal, 700091, India.
• 4 Swiss Tropical and Public Health Institute, Kreuzstrasse 2, 4123, Allschwil, Switzerland; University of Basel, 4003, Basel, Switzerland.
• 5 Global Health Medicines R&D, GSK, Tres Cantos, 28760, Spain.
• 6 Department of Microbiology & Immunology, Columbia University, Irving Medical Center, New York, 10032, NY, USA; Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine, Columbia University, Irving Medical Center, New York, 10032, NY, USA.
• 7 School of Medicine, Deakin University, Waurn Ponds, Victoria, 3216, Australia; Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Victoria, 3216, Australia.
• 8 Global Public Health, Janssen R&D LLC, La Jolla, 92121, USA.
• 9 MMV Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215, Geneva, Switzerland.
• 10 The Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, 3010, Australia. Electronic address: sleebs@wehi.edu.au.